Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback